Humana Inc. (NYSE:HUM) Shares Purchased by Osborne Partners Capital Management LLC

Osborne Partners Capital Management LLC grew its stake in shares of Humana Inc. (NYSE:HUM) by 0.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,799 shares of the insurance provider’s stock after acquiring an additional 188 shares during the quarter. Osborne Partners Capital Management LLC’s holdings in Humana were worth $6,588,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. increased its position in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the last quarter. Atwood & Palmer Inc. acquired a new stake in shares of Humana during the 3rd quarter worth $29,000. Hantz Financial Services Inc. purchased a new position in shares of Humana in the 2nd quarter worth $35,000. Family Firm Inc. acquired a new position in Humana in the second quarter valued at $37,000. Finally, Hollencrest Capital Management purchased a new stake in Humana during the second quarter valued at about $40,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

HUM stock opened at $260.73 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market cap of $31.39 billion, a P/E ratio of 18.60, a P/E/G ratio of 2.04 and a beta of 0.50. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The stock’s 50 day simple moving average is $308.31 and its 200 day simple moving average is $336.88.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the business earned $8.94 EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts predict that Humana Inc. will post 16.06 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.36%. Humana’s dividend payout ratio (DPR) is presently 25.25%.

Analysts Set New Price Targets

HUM has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft cut their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and reduced their price target for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Piper Sandler lowered shares of Humana from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Bank of America cut shares of Humana from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $376.00 to $247.00 in a research report on Wednesday, October 2nd. Finally, Barclays cut their price objective on Humana from $364.00 to $250.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Humana has an average rating of “Hold” and an average target price of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.